Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination - Wikidata - awgldk - TriplyDB

Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination

Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination

http://www.wikidata.org/entity/Q26998883

about

Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options Focus on JNJ-Q2, a novel fluoroquinolone, for the management of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections Insights into Newer Antimicrobial Agents Against Gram-negative Bacteria Pseudomonas aeruginosa ventilator-associated pneumonia management Relationship between ceftolozane-tazobactam exposure and selection for Pseudomonas aeruginosa resistance in a hollow-fiber infection model Ceftolozane/Tazobactam: a new option in the treatment of complicated gram-negative infections.Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches.Multidrug-Resistant Pseudomonas aeruginosa Infection in a Child with Cystic Fibrosis.Pseudomonas Endocarditis with an unstable phenotype: the challenges of isolate characterization and Carbapenem stewardship with a partial review of the literature.Ceftolozane/tazobactam for febrile UTI due to multidrug-resistant Pseudomonas aeruginosa in a patient with neurogenic bladder.Translational Modeling of Antibacterial Agents

P2860

Q21146707-906320E3-9346-419B-8225-E68402E74C72 Q26746197-AB529069-BFB9-4F0C-A27B-D896B220E1EC Q26751255-DB73B94E-3AC3-423F-9CFC-965F5F573644 Q26768365-BE25A2C1-C62A-407B-A61C-EB2892FDE630 Q34298994-A4604E4E-6A49-4452-8EAC-8F3C61DBE384 Q34688710-526A0F3E-5FE5-4CD9-AFB5-D82ECD942EB3 Q36761826-528A4DF8-EC25-4B57-BED7-5F27842FD19F Q37287648-4F2566B3-521D-4849-B80A-BBBD864F9760 Q40073768-1101A39D-00F2-4BD5-A007-55BCBD2A5254 Q40213320-E598EA0B-2920-4EDF-B8AE-1E054AD16A6C Q57240408-8AD0065A-2E33-4064-AFBA-B8CA600029A0

P2860

Ceftolozane/tazobactam: a novel antipseudomonal cephalosporin and β-lactamase-inhibitor combination

http://www.wikidata.org/entity/Q26998883

description

2013 nî lūn-bûn

@nan

2013 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Ceftolozane/tazobactam: a nove ...... actamase-inhibitor combination

@ast

Ceftolozane/tazobactam: a nove ...... actamase-inhibitor combination

@en

Ceftolozane/tazobactam: a nove ...... actamase-inhibitor combination

@nl

type

label

Ceftolozane/tazobactam: a nove ...... actamase-inhibitor combination

@ast

Ceftolozane/tazobactam: a nove ...... actamase-inhibitor combination

@en

Ceftolozane/tazobactam: a nove ...... actamase-inhibitor combination

@nl

prefLabel

Ceftolozane/tazobactam: a nove ...... actamase-inhibitor combination

@ast

Ceftolozane/tazobactam: a nove ...... actamase-inhibitor combination

@en

Ceftolozane/tazobactam: a nove ...... actamase-inhibitor combination

@nl

P1433

Q26998883-724C8CD6-DC01-4BA3-87C1-F1301A64094A

P1476

Q26998883-A9DC57B9-0DC1-42DC-9A87-C07C66CB7409

P2093

Q26998883-07DE2126-9D95-41FA-8122-46CC15A3AF72

Q26998883-5D204872-4633-4FDA-ACA0-F8B1C0057AE1

P2860

Q26998883-02BB6E1C-687A-4B6E-9A89-39BAA299D263

Q26998883-0956DCAD-D6CE-427D-AB49-9CA32DE28A83

Q26998883-2B94A0D8-7637-4AAA-8FF7-314211E8AB8F

Q26998883-331BC4D0-DBB2-4721-9181-D1983621F140

Q26998883-4E1DFA01-A714-404E-B56F-2D9D13A2AA48

Q26998883-4ED2F86F-F7AD-4435-BF37-475B1AEE47F1

Q26998883-54820ACE-F0CF-4903-AED0-142F8126E9AA

Q26998883-56B19792-9D3B-4E49-85B9-9D1E12EFAAC1

Q26998883-5D382AA4-A917-4B03-9EEA-23F22BA0B7DE

Q26998883-5FA199A7-3AF8-408C-84CE-095A56B0131D

P304

Q26998883-A7C5106F-612F-4762-AF3C-1D379405F5B4

P31

Q26998883-CAE22914-A2F3-4C6A-B064-4B964605424F

P3181

Q26998883-3665F94C-A4A3-46D6-A3DB-912FE3D07F37

P356

Q26998883-730D0F97-CA98-4565-8622-E9B57C282D66

P407

Q26998883-DEF7580C-2108-4F8E-B749-9183DAAB0963

P478

Q26998883-3445A46F-53DA-430F-A2E5-5AFE3E04AF1C

P50

Q26998883-E8DBE30F-B62D-4F04-A77B-6170E0E2227F

P577

Q26998883-12522869-231E-48C0-A1D9-AD459D4BEDC6

P698

Q26998883-C63AD4DE-A234-4951-8B84-EB21C5A299A5

P932

Q26998883-32DFFFCE-4631-4FBD-8F5F-F6B05FED73BD

P3181

P356

P1433

Infection and Drug Resistance

P1476

Ceftolozane/tazobactam: a nove ...... actamase-inhibitor combination

@en

P2093

Donald I Hsu

http://www.w3.org/2001/XMLSchema#string

Mai-Chi Hong

http://www.w3.org/2001/XMLSchema#string

P2860

Estimating health care-associated infections and deaths in U.S. hospitals, 2002

Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE

Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America

Multidrug resistance among gram-negative pathogens that caused healthcare-associated infections reported to the National Healthcare Safety Network, 2006-2008.

Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010.

National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004.

Antipseudomonal antibiotics.

Attributable hospital cost and length of stay associated with health care-associated infections caused by antibiotic-resistant gram-negative bacteria.

Pharmacokinetics and safety of CXA-101, a new antipseudomonal cephalosporin, in healthy adult male and female subjects receiving single- and multiple-dose intravenous infusions.

Multidrug-resistant Pseudomonas aeruginosa: risk factors and clinical impact.

P304

215-223

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

990994

http://www.w3.org/2001/XMLSchema#string

P356

10.2147/IDR.S36140

http://www.w3.org/2001/XMLSchema#string

P407

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Mark Bounthavong

P577

2013-11-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24348053

http://www.w3.org/2001/XMLSchema#string

P932

3848746

http://www.w3.org/2001/XMLSchema#string